Key Takeaways HSIC is set to report Q4 2025 results on Feb. 24, with revenues projected to rise 4.5% year over year.Henry Schein's Global Specialty Products revenues are expected to grow 5.9% on implant strength.HSIC's Global Technology sales are projected to jump 9.7% on SaaS and cloud momentum.Henry Schein, Inc. (HSIC) is scheduled to release fourth-quarter 2025 results on Feb. 24, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.38, which su ...

Core Insights - Veracyte, Inc. (VCYT) is set to report its fourth-quarter 2025 results on February 25, with expectations of strong performance based on previous earnings surprises [1][9] Financial Performance - The Zacks Consensus Estimate for revenues is $138.7 million, indicating a 16.9% increase from the previous year [2] - The Zacks Consensus Estimate for EPS is 41 cents, reflecting a 13.9% year-over-year growth [2] - Earnings estimates have increased by 2.5% in the last 30 days, suggesting positive sentiment leading up to the earnings report [3] Business Segments - The core testing business is anticipated to show solid revenue growth, driven by strong volumes in Decipher and Afirma tests [4][9] - Decipher Prostate tests delivered approximately 26,700 tests in the third quarter, marking 14 consecutive quarters of over 25% year-over-year volume growth, a trend expected to continue [5] - Test volumes in the high-risk localized segment are also expected to have increased, supported by ongoing research and clinical adoption [6] Product Insights - Product volume in the third quarter was around 2,200 tests, with a year-over-year revenue growth of 4%, a trend expected to persist [7] - However, management has indicated a decline in product gross margin due to a transition to a contract manufacturing model [7][9] Market Position - VCYT has an Earnings ESP of +7.98% and a Zacks Rank of 2 (Buy), indicating a higher likelihood of beating earnings estimates [11] - The company is facing challenges in its biopharma revenues and expects lower product gross margins in the fourth quarter due to restructuring efforts [9][10]

Market Overview - The Uterine Fibroid Market was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033, growing at a CAGR of 7.63% from 2026 to 2033 [1][8]. Growth Drivers - The market is expanding due to the increased incidence of uterine fibroids among women of childbearing age, with approximately 70 to 80% of women experiencing fibroids by age 50 [2]. - Rising healthcare infrastructure in emerging markets and increased awareness regarding fibroid treatment options are also contributing to market growth [5]. Treatment Trends - There is a significant trend towards minimally invasive techniques for treating uterine fibroids, with adoption rates rising by over 60% in the past five years [4]. - Minimally invasive procedures are expected to grow at the fastest CAGR of 8.63% from 2026 to 2033, driven by advancements in technology and patient preference for less invasive options [11]. Market Segmentation - By Type: Submucosal Fibroids dominated with 36.24% in 2025, while Intramural Fibroids are expected to grow at the fastest CAGR of 8.20% from 2026 to 2033 [9][10]. - By Treatment Type: Surgical Procedures held 38.45% in 2025, with Minimally Invasive Procedures projected to grow at 8.63% CAGR [11]. - By Technology: Laparoscopic Surgery accounted for 36.58% in 2025, with MRI-Guided Focused Ultrasound expected to grow at 8.83% CAGR [12]. - By End-User: Hospitals & Clinics dominated with 47.49% in 2025, while Ambulatory Surgical Centers are expected to grow at 8.43% CAGR [13]. Regional Insights - The U.S. Uterine Fibroid Market was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% [14]. - North America is expected to hold a 45.32% market share in 2025, while Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033 [15]. Recent Developments - In January 2024, Pfizer Canada announced the availability of MYFEMBREE® for treating uterine fibroids and endometriosis [17]. - In September 2024, Theramex announced the first commercial sale of Yselty® in Germany, marking a new treatment option for women with moderate to severe symptoms of uterine fibroids [17].

Core Insights - Maverick Capital Ltd. established long positions in Google C, Applied Materials, Boston Scientific, Visa, and Camden Property during the fourth quarter [1] - The firm increased its holdings in TSMC, NVIDIA, GFL Environment, and Carvana [1] - Maverick Capital completely exited positions in Kenvue, US Bancorp, AMD, Danaher, and Insmed [1] - The company reduced its stakes in Nubank, Disney, Merit Medical, Acadia Health, and Sherwin-Williams [1] - The firm maintains significant positions in NVIDIA, Microsoft, Amazon, TSMC, and Google C [1]

Core Insights - Charles River Laboratories International, Inc. (CRL) is set to report its fourth-quarter 2025 results on February 18, with adjusted earnings per share (EPS) of $2.43 in the last quarter exceeding the Zacks Consensus Estimate by 4.74% [1] Financial Estimates - The Zacks Consensus Estimate for CRL's revenues is $985.9 million, indicating a 1.7% decline from the previous year [2] - The Zacks Consensus Estimate for EPS is $2.33, reflecting a 12.4% year-over-year decrease [2] Performance and Trends - Earnings estimates have remained unchanged over the past 30 days, with a consistent performance noted in the previous quarters [3] - The RMS segment is expected to see a 0.5% revenue increase in Q4 2025, driven by large research model product revenues, particularly from Noveprim and GEMS [8] Collaborations and Revenue Drivers - CRL engaged in collaborations with Toxys and X-Chem, which may positively impact revenues through enhanced service offerings [4][5] - Despite NIH budget cuts, revenues from academic and government clients are anticipated to remain favorable, although early-stage biotech demand may be constrained by funding challenges [7] Segment Performance - The Discovery and Safety Assessment (DSA) segment is projected to experience a 3.9% revenue decline year-over-year due to budget pressures from biopharmaceutical clients [11] - The Manufacturing Solutions segment is expected to benefit from strong performance in the Microbial Solutions business, with a projected revenue increase of 2.3% year-over-year [12][14] Market Position and Outlook - CRL's overall pricing environment is expected to remain stable, but the DSA segment may face challenges impacting overall revenues [11] - The company has a Zacks Rank of 3, indicating a hold position, with an Earnings ESP of -0.46%, suggesting a lower likelihood of beating estimates [15]

Core Insights - West Pharmaceutical Services, Inc. (WST) reported adjusted fourth-quarter 2025 earnings per share (EPS) of $2.04, a 12.1% increase year over year, exceeding the Zacks Consensus Estimate by 11.5% [1] - The company achieved revenues of $805 million in the fourth quarter, reflecting a 7.5% year-over-year growth, surpassing the Zacks Consensus Estimate by 1.4% [2] - Full-year 2025 revenues reached $3.07 billion, marking a 6.3% increase from 2024, with organic revenues up 4.3% year over year [3] Financial Performance - Adjusted EPS for the full year was $7.29, an 8% increase from 2024 [1] - GAAP EPS for the fourth quarter was $1.82, a 2.2% improvement from the previous year [1] - Gross profit for the quarter increased by 11.1% to $303.9 million, with a gross margin expansion of 130 basis points to 37.8% [10] Segment Performance - Proprietary Products segment reported revenues of $661.8 million, up 7.8% year over year, with high-value products accounting for 48% of net sales [7][8] - Contract-Manufactured Products segment revenues totaled $143.2 million, reflecting a 6.2% year-over-year increase [9] Guidance and Outlook - For Q1 2026, WST expects sales between $770 million and $790 million, with EPS projected in the range of $1.65-$1.70 [14] - Full-year 2026 revenues are anticipated to be between $3.21 billion and $3.27 billion, with organic net sales expected to grow 5-7% [15] - Adjusted EPS for 2026 is projected to be in the range of $7.85-$8.20 [16] Strategic Insights - The company attributes its strong performance to consistent execution of its growth strategy, particularly in the high-value product segment [18] - Management expects the momentum to continue into 2026, focusing on operational discipline and growth sustainability [18] - The guidance reflects steady demand fundamentals and favorable currency tailwinds [19]

Core Insights - West Pharmaceutical Services (WST) reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.83 per share, and showing an increase from $1.82 per share a year ago, resulting in an earnings surprise of +11.21% [1] - The company achieved revenues of $805 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.35% and increasing from $748.8 million year-over-year [2] - West Pharmaceutical has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.64, with expected revenues of $759.74 million, while for the current fiscal year, the EPS estimate is $7.67 on revenues of $3.24 billion [7] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 2 (Buy), suggesting expected outperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Baxter International Inc. is set to release its fourth-quarter 2025 results on February 12, with earnings expected to decline year-over-year despite a slight revenue increase [2][3][9] Q4 Estimates - Revenue consensus is estimated at $2.79 billion, reflecting a 1.5% increase from the previous year, while earnings are projected at 53 cents per share, indicating an 8.6% decline [3][9] - Total revenues from continuing operations are expected to decline by 2.7% at constant currency to $2.79 billion, with adjusted earnings per share anticipated to drop by 9.3% [3] Important Factors to Note - The upcoming quarterly results are likely to show operational challenges, particularly in infusion therapies and certain pharmaceutical categories, which may impact performance [4] - Revenue growth is expected to be muted due to softness in key hospital-based product lines, particularly within the Infusion Therapies & Technologies division [5] Segment Performance - The Medical Products & Therapies segment is expected to be negatively impacted by issues with the Novum IQ large volume pump, leading to lost sales and customer transitions to alternative platforms [6][7] - Advanced Surgery sales are anticipated to show double-digit growth driven by strong demand for hemostats and sealants, partially offsetting weaknesses in the ITT division [8] - The Healthcare Systems & Technologies segment is likely to support top-line growth due to strong order momentum, particularly in Care & Connectivity Solutions [8] Pharmaceuticals Outlook - Quarterly results in Pharmaceuticals are expected to be mixed, with solid growth in drug compounding sales outside the U.S., while Injectables & Anesthesia may face challenges due to shifts in hospital protocols [11] Earnings Prediction Model - The current model does not predict an earnings beat for Baxter, as the Earnings ESP is 0.00% and the Zacks Rank is 3 (Hold) [13][14]

Core Insights - DexCom, Inc. (DXCM) is set to report its fourth-quarter 2025 results on February 12, with adjusted earnings per share (EPS) of 61 cents in the last quarter exceeding the Zacks Consensus Estimate by 7% [1] Group 1: Q4 Estimates and Preliminary Results - The Zacks Consensus Estimate for Q4 revenues is $1.25 billion, reflecting a 12.4% increase year over year, while the earnings estimate is 65 cents, indicating a 44.4% growth [2] - Preliminary results suggest Q4 2025 total revenues of approximately $1.26 billion, up 13% from Q4 2024, with U.S. revenues projected at $892 million (11% growth) and international revenues expected to rise 18% to around $368 million [3] Group 2: Factors Influencing Performance - Recovery in new customer starts following G7 deployment issues and quality-related disruptions is a critical factor for Q4 performance [4] - Management noted that new starts in Q3 were slightly below record levels due to sensor deployment issues, but improvements in sensor performance and educational samples are expected to enhance new-start momentum in Q4 [5] - Gross margins are anticipated to improve as supply chain pressures ease, with management indicating that scrap rates and freight costs have improved sequentially [6][7] Group 3: International Growth and Market Dynamics - Sustained international momentum and broader adoption among type 2 diabetes patients are expected to positively impact earnings, with accelerating international growth supported by coverage expansions in markets like France and Canada [10] - The ability to convert increased access into volume growth in Q4 is likely to significantly influence earnings outcomes [11] Group 4: Seasonal Trends and Future Outlook - Investors are likely to focus on exit-rate trajectories adjusted for seasonality, as the fourth quarter now contributes a smaller share of full-year revenues [12] - Despite potentially modest headline growth, underlying patient growth remains solid, prompting investors to assess trends in user growth and pricing stability for a healthy baseline in 2026 [13] Group 5: Earnings Prediction - The Zacks model predicts an earnings beat for DexCom, supported by a positive Earnings ESP of +3.08% and a Zacks Rank of 3 (Hold) [14][15]

Core Insights - Labcorp Holdings Inc. is set to report its fourth-quarter 2025 results on February 17, with adjusted earnings of $4.18 in the last quarter, exceeding the Zacks Consensus Estimate by 1.21% [1] - The company has consistently surpassed earnings estimates over the past four quarters, with an average surprise of 2.68% [1] Q4 Estimates for Labcorp - The Zacks Consensus Estimate for Labcorp's fourth-quarter 2025 revenues is $3.55 billion, indicating a 6.6% increase from the previous year [2] - The estimated EPS for the fourth quarter is projected to improve by 15% to $3.95 [2] Estimate Revision Trend - Earnings estimates for Labcorp's fourth quarter have remained stable at $3.95 over the past 30 days [3] Factors Influencing Performance - The Diagnostics Laboratories segment is expected to maintain strong momentum due to organic growth and acquisitions, including the purchase of Incyte Diagnostics' clinical pathology business and other assets [4] - Demand for core tests in high-growth specialty areas such as oncology and women's health is anticipated to remain robust, supported by new testing capabilities [5] - The Labcorp OnDemand channel is likely to see continued strong adoption, contributing to a projected 7% year-over-year revenue increase in the Diagnostics segment [6] Biopharma Laboratory Services - The Biopharma Laboratory Services unit is expected to grow by 3.1% year-over-year, despite challenges from restructuring and delayed study starts [8][10] - The Central Laboratories component is anticipated to continue benefiting from its strength, although Early Development revenues faced impacts from previous quarter delays [9] Technological Advancements - Labcorp's increased use of science and technology, including the introduction of AI tools like Test Finder, is expected to enhance growth and operational efficiency [10] - Investments in digital and AI capabilities are aimed at improving core laboratory operations, with the Launchpad initiative targeting annual savings of $100-$125 million [11]